ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15
0 Assignments
0 Petitions
Accused Products
Abstract
To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
-
Citations
39 Claims
-
1-13. -13. (canceled)
-
14. A method of treating or preventing abnormal bone metabolism comprising administering a pharmaceutical composition comprising a monoclonal antibody or a functional fragment of the antibody, wherein the monoclonal antibody or the functional fragment of the monoclonal antibody binds one or more polypeptides comprising an amino acid sequence selected from the group consisting of:
-
(a) amino acid residues 21 to 328 of the amino acid sequence represented by SEQ ID NO;
2;(b) amino acid residues 1 to 260 of the amino acid sequence represented by SEQ ID NO;
2;(c) amino acid residues 21 to 260 of the amino acid sequence represented by SEQ ID NO;
2;(d) amino acid residues 21 to 341 of the amino acid sequence represented by SEQ ID NO;
4;(e) amino acid residues 1 to 258 of the amino acid sequence represented by SEQ ID NO;
4; and(f) amino acid residues 21 to 258 of the amino acid sequence represented by SEQ ID NO;
4,wherein said antibody or a functional fragment of the antibody inhibits osteoclast formation and/or osteoclastic bone resorption. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
-
-
36. A method of treating or preventing abnormal bone metabolism comprising administering a pharmaceutical composition comprising a monoclonal antibody or a functional fragment of the antibody, wherein the monoclonal antibody or the functional fragment of the monoclonal antibody has the same epitope specificity as an antibody produced by a hybridoma selected from the group consisting of hybridoma #32A1 (FERM BP-10999), and hybridoma #41B1 (FERM BP-11000).
-
37. A method of treating or preventing abnormal bone metabolism comprising administering a pharmaceutical composition comprising a monoclonal antibody or a functional fragment of the antibody, wherein the monoclonal antibody or the functional fragment of the monoclonal antibody competes with an antibody produced by a hybridoma selected from the group consisting of hybridoma #32A1 (FERM BP-10999), and hybridoma #41B1 (FERM BP-11000).
-
38. A method of treating or preventing abnormal bone metabolism comprising administering a pharmaceutical composition comprising a monoclonal antibody or a functional fragment of the antibody, wherein the monoclonal antibody or the functional fragment of the monoclonal antibody is produced by a hybridoma selected from the group consisting of hybridoma #32A1 (FERM BP-10999) and hybridoma #41B1 (FERM BP-11000).
-
39. A method of treating or preventing abnormal bone metabolism comprising administering a pharmaceutical composition comprising a monoclonal antibody or a functional fragment of the antibody, wherein the monoclonal antibody or the functional fragment of the monoclonal antibody binds one or more polypeptides comprising an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of:
-
(a) a nucleotide sequence represented by SEQ ID NO;
1;(b) a nucleotide sequence represented by SEQ ID NO;
3;(c) a nucleotide sequence represented by SEQ ID NO;
19; and(d) a nucleotide sequence represented by SEQ ID NO;
43,wherein said antibody or a functional fragment of the antibody inhibits osteoclast formation and/or osteoclastic bone resorption.
-
Specification